FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212909438> ?p ?o ?g. }

• W4212909438 endingPage "185" @default.
• W4212909438 startingPage "185" @default.
• W4212909438 abstract "185 Background: Short-term effectiveness of COVID-19 vaccination is widely demonstrated, but the emerging real-world data suggest that immunity may wane over-time (Levin et al. NEJM 2021). Herein we aimed to explore the long-term efficacy of the COVID-19 vaccination among pts with genitourinary cancer. Methods: In this study, pts with genitourinary malignancies (prostate, kidney, and bladder cancers) who had not received COVID-19 vaccination were included. Blood samples were collected prior to and after one dose of either an adenovirus- or mRNA-based COVID-19 vaccine at the 2- and 6-month timepoints. Additional blood samples from pts receiving systemic treatment were collected at 3 consecutive therapy cycles following vaccination. Antibody titers were assessed using the SCoV-2 Detect IgG ELISA assay and results were reported as immune status ratios (ISR). T-cell receptor (TCR) repertoire sequencing was performed using the MiXCR software (MiLabs) and custom strips were used to assess TCR abundance and homology clustering. Results: A total of 183 pts were enrolled, and 136 pts provided baseline blood samples. Among these, 59 (8:51 F:M) provided samples for both the 2- and 6-month timepoints by the 10/6/2021 data cut-off. In this subset of pts, median age was 66 (range 48-85) and 33 (55.9%), 25 (42.4%), and 1 (1.7%) pts had prostate, kidney, and bladder cancer, respectively. A majority of the pts (93.2%) were on systemic treatment with 23.7% on immune checkpoint inhibitors, 18.6% on targeted agents, and 1.7% on chemotherapy. The most commonly administered vaccines were BNT162b2 (61.0%) followed by mRNA-1273 (37.3%) and Ad26.COV2.S (1.7%). The mean (±standard deviation) ISR values at baseline and 2 months were 0.68±1.59 and 6.62±1.75, respectively. At the 6-month timepoint, mean ISR was 5.46±1.61; this was significantly lower than the 2-month antibody titers (p < 0.0001), and reflects a reduction of 17.6%. Further data on TCR sequencing will be presented at the meeting. Conclusions: To our knowledge, this is the first data assessing the long-term serologic outcomes of COVID-19 vaccination in pts with cancer. Our data suggest waning immunity over time in cancer pts. Strategies to prolong host immunity against SARS COV-2 (e.g., booster vaccination) are likely warranted." @default.
• W4212909438 created "2022-02-24" @default.
• W4212909438 creator A5003826371 @default.
• W4212909438 creator A5005719127 @default.
• W4212909438 creator A5012361531 @default.
• W4212909438 creator A5020250473 @default.
• W4212909438 creator A5021244561 @default.
• W4212909438 creator A5028660468 @default.
• W4212909438 creator A5032713796 @default.
• W4212909438 creator A5041033274 @default.
• W4212909438 creator A5044516598 @default.
• W4212909438 creator A5048303301 @default.
• W4212909438 creator A5058492722 @default.
• W4212909438 creator A5064808332 @default.
• W4212909438 creator A5071490548 @default.
• W4212909438 creator A5073523275 @default.
• W4212909438 creator A5073546222 @default.
• W4212909438 creator A5084835754 @default.
• W4212909438 creator A5085928090 @default.
• W4212909438 creator A5086966607 @default.
• W4212909438 creator A5090821229 @default.
• W4212909438 creator A5091696839 @default.
• W4212909438 date "2022-02-20" @default.
• W4212909438 modified "2023-09-27" @default.
• W4212909438 title "Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies." @default.
• W4212909438 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.185" @default.
• W4212909438 hasPublicationYear "2022" @default.
• W4212909438 type Work @default.
• W4212909438 citedByCount "0" @default.
• W4212909438 crossrefType "journal-article" @default.
• W4212909438 hasAuthorship W4212909438A5003826371 @default.
• W4212909438 hasAuthorship W4212909438A5005719127 @default.
• W4212909438 hasAuthorship W4212909438A5012361531 @default.
• W4212909438 hasAuthorship W4212909438A5020250473 @default.
• W4212909438 hasAuthorship W4212909438A5021244561 @default.
• W4212909438 hasAuthorship W4212909438A5028660468 @default.
• W4212909438 hasAuthorship W4212909438A5032713796 @default.
• W4212909438 hasAuthorship W4212909438A5041033274 @default.
• W4212909438 hasAuthorship W4212909438A5044516598 @default.
• W4212909438 hasAuthorship W4212909438A5048303301 @default.
• W4212909438 hasAuthorship W4212909438A5058492722 @default.
• W4212909438 hasAuthorship W4212909438A5064808332 @default.
• W4212909438 hasAuthorship W4212909438A5071490548 @default.
• W4212909438 hasAuthorship W4212909438A5073523275 @default.
• W4212909438 hasAuthorship W4212909438A5073546222 @default.
• W4212909438 hasAuthorship W4212909438A5084835754 @default.
• W4212909438 hasAuthorship W4212909438A5085928090 @default.
• W4212909438 hasAuthorship W4212909438A5086966607 @default.
• W4212909438 hasAuthorship W4212909438A5090821229 @default.
• W4212909438 hasAuthorship W4212909438A5091696839 @default.
• W4212909438 hasConcept C121608353 @default.
• W4212909438 hasConcept C126322002 @default.
• W4212909438 hasConcept C133507102 @default.
• W4212909438 hasConcept C159654299 @default.
• W4212909438 hasConcept C203014093 @default.
• W4212909438 hasConcept C22070199 @default.
• W4212909438 hasConcept C2780192828 @default.
• W4212909438 hasConcept C71924100 @default.
• W4212909438 hasConcept C8891405 @default.
• W4212909438 hasConceptScore W4212909438C121608353 @default.
• W4212909438 hasConceptScore W4212909438C126322002 @default.
• W4212909438 hasConceptScore W4212909438C133507102 @default.
• W4212909438 hasConceptScore W4212909438C159654299 @default.
• W4212909438 hasConceptScore W4212909438C203014093 @default.
• W4212909438 hasConceptScore W4212909438C22070199 @default.
• W4212909438 hasConceptScore W4212909438C2780192828 @default.
• W4212909438 hasConceptScore W4212909438C71924100 @default.
• W4212909438 hasConceptScore W4212909438C8891405 @default.
• W4212909438 hasIssue "6_suppl" @default.
• W4212909438 hasLocation W42129094381 @default.
• W4212909438 hasOpenAccess W4212909438 @default.
• W4212909438 hasPrimaryLocation W42129094381 @default.
• W4212909438 hasRelatedWork W155301942 @default.
• W4212909438 hasRelatedWork W1566410842 @default.
• W4212909438 hasRelatedWork W1572283981 @default.
• W4212909438 hasRelatedWork W2019574320 @default.
• W4212909438 hasRelatedWork W2143941734 @default.
• W4212909438 hasRelatedWork W3048051248 @default.
• W4212909438 hasRelatedWork W3193012584 @default.
• W4212909438 hasRelatedWork W4200563690 @default.
• W4212909438 hasRelatedWork W4206914007 @default.
• W4212909438 hasRelatedWork W4221063257 @default.
• W4212909438 hasVolume "40" @default.
• W4212909438 isParatext "false" @default.
• W4212909438 isRetracted "false" @default.
• W4212909438 workType "article" @default.